Edition:
United Kingdom

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

21 Nov 2017

Brexit gets real for drugmakers as regulator moves to Amsterdam

LONDON Drugmakers are racing to implement Brexit contingency plans to prepare for a jolt to their regulatory system as the European Medicines Agency is uprooted from London to Amsterdam. | Video

21 Nov 2017

Brexit gets real for drugmakers as regulator moves to Amsterdam

LONDON Drugmakers are racing to implement Brexit contingency plans to prepare for a jolt to their regulatory system as the European Medicines Agency is uprooted from London to Amsterdam.

20 Nov 2017

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

20 Nov 2017

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

16 Nov 2017

$1 million price tag in spotlight as gene therapy becomes reality

LONDON Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers.

16 Nov 2017

AstraZeneca ticks another box as U.S. approves severe asthma drug

(This version of the Nov.15 story corrects the spelling of the drug in paragraphs 8, 9)

14 Nov 2017

Biotech firms race to recruit good bugs in war on cancer

Biotech companies are competing to develop medicines using "bugs as drugs" to fight cancer, building on the latest scientific findings that patients with high levels of good gut bacteria are more likely to respond to modern immunotherapy.

09 Nov 2017

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline .

09 Nov 2017

AstraZeneca sales decline slows as it waits for medicine to work

LONDON AstraZeneca's drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

09 Nov 2017

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline .

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,409.64 -7.60 -0.10%
DAX 13,059.84 + 51.29 +0.39%
CAC 40 5,390.46 + 10.92 +0.20%
TR Europe 185.64 + 1.15 +0.62%
GBP/USD 1.3335 +0.00%
GBP/EUR 1.1177 +0.00%
EUR/USD 1.1928 +0.00%
Gold 1,291.60 +0.00 +0.00%
Oil 58.97 +0.95 +1.64%
Corn 342.00 -3.25 -0.94%